Contact
searchSearch
HMP Global
Login

Cholangiocarcinoma Resource Center

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
04/24/2025
Lalan Wilfong, MD
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
04/24/2025
Journal of Clinical Pathways
Videos
Confronting Intersectional Stigmas Across the Cancer Care Continuum
04/24/2025
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH,...
04/24/2025
Journal of Clinical Pathways
News
EHR-Based Model Accurately Identifies High-Risk Patients for Gastric Cancer
04/24/2025
Lisa Kuhns, PhD, MD
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record...
04/24/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Strengthening Pathway-Driven Care Through Payer Collaboration
04/23/2025
Gordon Kuntz; Lalan Wilfong, MD
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology...
04/23/2025
Journal of Clinical Pathways
Steven Monda, MD
Videos
Evaluating the Performance of Biomarkers from Metastatic vs Primary Sites in Clear Cell Renal Cell Carcinoma
04/23/2025
Steven Monda, MD
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his...
04/23/2025
Journal of Clinical Pathways
Hafron Headshot
Videos
Developing a National Pathway Framework for Prostate Cancer: Insights from Solaris Health
04/17/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
04/17/2025
Journal of Clinical Pathways
Adam Brufsky, MD
Interview
The Overall Cost-Effectiveness of Adjuvant Ribociclib in ER+ Early Breast Cancer
04/15/2025
Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses...
04/15/2025
Journal of Clinical Pathways
Figlin
Videos
Durable Responses With Belzutifan Plus Cabozantinib in Advanced RCC: Updated Findings From LITESPARK-003
04/15/2025
Robert A. Figlin, MD
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert...
04/15/2025
Journal of Clinical Pathways
Original Research
Lessons Learned From the Development and Implementation of a Shared Decision-Making Process for Severe Stroke Using a Digital Communication Platform
04/15/2025
Akila Visvanathan, PhD; Sarah Morton, PhD; Allan Macraild, MSc; Polly Black, MSc; Sophie Gilbert, MSc; Mark Barber, MD; Martin Dennis, MD; Richard O'Brien, MD; Gillian Mead, MD
This study explored the use of a digital platform to support shared decision-making in a stroke unit, revealing critical barriers that must be addressed to improve patient-centered outcomes.
This study explored the use of a digital platform to support shared decision-making in a stroke unit, revealing critical barriers that must be addressed to improve patient-centered outcomes.
This study explored the use of a...
04/15/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
JCP March/April 2025

Current Issue

April 2025
Volume 11
Issue 2
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use